Clinical Study On Hypercoagulable State Among Lung Cancer Patients

Backgrounds The view that patients with lung cancer are easily accompanied byhypercoagulable state has become medical consensus. Not only the risk of thrombosisbut also the progression of cancer can be deteriorated by blood hypercoagulability.Anticoagulation therapy is important for lung cancer patients. But, mosthypercoagulable state distribution characteristics have been collected by theretrospective studies of VTE patients, and few prospective studies were carried out.Aim To observe hypercoagulable state distribution characteristics among clinicalfeatures based lung cancer groups. In order to find the relationship between clinicalfeatures and hypercoagulable state of lung cancer.Methods Between April of2012and December of2012,92patients of initialtreatment lung cancer were enrolled in this study. Collect the gender, histological type,stage, comorbidities, ECOG score, BMI, habits, WBC, LYM, RBC, HBG, PLT,albumin. Analysis of above information and summarize the clinical and laboratorycharacteristics of lung cancer patients with hypercoagulable state.Results①Female group had a significant high risk for the occurrence ofhypercoagulable state (χ2=4.396, P=0.036).②It was a positive correlationbetween age and the risk for the occurrence of hypercoagulable state (r=0.3，P=0.004).③The NSCLC group had a significant high risk for the occurrence ofhypercoagulable state (χ2=5.190, P=0.023)； Compared to SCLC group，adenocarcinoma group had a significant high risk for the occurrence ofhypercoagulable state (χ2=5.828, P=0.016).④It was a positive correlation betweenECOG and the risk for the occurrence of hypercoagulable state (r=0.214，P=0.049).⑤Compared to the group with no comorbidities, diabetes mellitus group (χ2=8.280，P=0.011)，hypertension group，(χ2=7.462，P=0.006), infection group (χ2=6.449，P=0.011), pleural effusion group (χ2=4.741，P=0.029), had a significanthigh risk for the occurrence of hypercoagulable state. It was a positive correlationbetween comorbidities and the risk for the occurrence of hypercoagulable state (r= 0.359，P=0.001).⑥It was a positive correlation between WBC (r=0.259, P=0.015)and the risk for the occurrence of hypercoagulable state, as well as PLT (r=0.340, P=0.015). It was a negative correlation between albumin and the risk for theoccurrence of hypercoagulable state (r=-0.308，P=0.003).⑦For SCLC group andNSCLC group, the risk for the occurrence of hypercoagulable state was increasedrespectively when patients with later stage, but no statistical differences wereobserved among different stages.⑧The risk for the occurrence of hypercoagulablestate was increased when patients with high BMI, but no statistical differences wereobserved.⑨No statistical difference was observed between smoker group andcontrol group.⑩Female, age≥62.5ys, PLT≥242.5×109/L and accompanied withcomorbidities (hypertension, pleural effusion, infection, diabetes mellitus, otherdiseases) were independent trisk factors for the occurrence of hypercoagulable state;the OR values were6.611(95%CI:1.334-32.753),5.991(95%CI:1.534-23.397),11.783(95%CI:2.642-52.553),4.698(95%CI:1.122-19.666), respectively.Conclusions1. Female, age≥62.5ys, PLT≥242.5×109/L and accompanied withcomorbidities (hypertension, pleural effusion, infection, diabetes mellitus, otherdiseases) were independent trisk factors for the occurrence of hypercoagulable state.2.Other important results: There was positive correlation between white blood cellcounts and the risk for the occurrence of hypercoagulable state, as well as ECOGperformance status. NSCLC patients had a significant high risk for the occurrenceof hypercoagulable state; the highest risk patients were those with adenocarcinomalung cancer. The risk for the occurrence of hypercoagulable state was increasedwhen patients with high BMI, but no statistical differences were observed.